论文部分内容阅读
疏甲丙脯酸(captopril CPT)自1977年问世以来,是临床上第一个口服有效的血管紧张素转换酶(A CE)抑制剂。它对多种高血压均有明显的降压作用,并能改善充血性心力衰竭的心脏功能,治疗心衰。而且在一些重症心衰和难治性心衰有较好的疗效。近年来还发现它对多种疾病有治疗作用。一、治疗高血压作用机理:抑制ACE,使血管紧张素I(ATI)转变血管紧张素Ⅱ受阻,具有生理性A7Ⅱ形成障碍,不但可以抑制血管收缩,而且使醛固酮分泌减少,肾脏的排钠增加,从而使血压下降;抑制激肽酶Ⅱ,使激肽降解灭活受阻,因激肽(如缓激肽)积聚,使血管扩张,血压下降;可能使前列腺素E(PGE)或PGE_2的代谢物PGE-M增
Captopril CPT has been the first clinically effective inhibitor of angiotensin-converting enzyme (A CE) since its introduction in 1977. It has significant antihypertensive effect on a variety of high blood pressure, and can improve the heart function of congestive heart failure, the treatment of heart failure. And in some severe heart failure and refractory heart failure have a better effect. In recent years, it has also found that it has a therapeutic effect on various diseases. First, the treatment of hypertension Mechanism of action: inhibition of ACE, angiotensin I (ATI) conversion of angiotensin Ⅱ blocked with physiological A7 Ⅱ formation disorders, not only can inhibit vasoconstriction, but also to reduce the secretion of aldosterone, kidney sodium increased , Thereby reducing blood pressure; inhibition of kininase II, inactivation of inhibition of kinin blocked by the accumulation of kinins (such as bradykinin), the vasodilation, blood pressure; may make prostaglandin E (PGE) or PGE 2 metabolism PGE-M increase